摘要
目的:研究乳腺癌耐药蛋白(BCRP)在乳腺癌组织中的表达,评估其在乳腺癌预后中的作用。方法:采用免疫组织化学方法(IHC)检测60例手术切除的乳腺癌组织中BCRP的表达,并分析其与临床病理特征的关系及对预后的影响。结果:①BCRP在乳腺癌组织中的阳性表达率为35%(21/60例);②腋淋巴结或激素受体阳性者BCRP表达水平显著高于腋淋巴结阴性者和激素受体阴性者(P<0.05),BCRP表达与年龄、月经状况、肿瘤大小和组织学分级均无关(P>0.05);③Kaplan-Meier生存分析结果表明BCRP表达与无病生存期显著相关(P<0.05),但和总生存期无关(P>0.05);④Cox单因素和多因素分析都显示肿瘤大小、淋巴结转移和雌激素受体(ER)与无病生存期和总生存期显著相关(P<0.05),另外孕激素受体与总生存期(P<0.05)显著相关。结论:BCRP在乳腺癌组织中具有一定的表达水平,与乳腺癌患者的无病生存期有关,而与总生存期无关。
Purpose: The aim of the present study was to investigate the expression of breast cancer resistance protein (BCRP) in primary breast carcinoma and to determine whether such expression can predict survival. Methods: Expression of BCRP in 60 breast cancer patients was determined by immunohistochemistry on formalin-fixed, paraffin-embedded tumor section. The relationship between the expression of BCRP with the clinicphathological characteristics and the prognosis of breast cancer patients were also analyzed. Results: ①BCRP expression was observed in 21 of 60 (35%) cases.② BCRP expression was more frequently observed in patients with lymph node metastasis or hormone receptor (P < 0. 05) . No relation can be established between expression of BCRP and other clinicophathological parameters (P>0. 05) .③Kaplan-Meier analyses revealed that BCRP expression associated only with disease-free survival (DFS) (P < 0. 05) and not with overall survival (OS) (P>0. 05) . ④In univariate and multivariate Cox regression analyses, tumor size, lymph node metastasis and estrogen receptor (ER) was associated with DFS and OS (P < 0. 05) . In addition, progestin receptor (PR) was also associated with OS (P < 0. 05) . Conclusions: The results suggest that BCRP is expressed in primary breast carcinoma and is an independent predictive factor for DFS, but do not for OS.
出处
《中国癌症杂志》
CAS
CSCD
2004年第2期123-126,共4页
China Oncology
基金
深圳市科技计划资助项目(No.200204018)。
关键词
乳腺癌
乳腺癌耐药蛋白
预后
免疫组织化学
breast carcinoma
breast cancer resistance protein
prognosis
immunohistochemistry
